Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Pulmonary Disease, Chronic Obstructive 1Lung Neoplasms 1Disease 1Diabetes Mellitus, Type 2 1

Interventions

Blood Specimen Collection 137Surveys and Questionnaires 131Specimen Handling 57Observation 55Radiotherapy 44Interviews as Topic 35Drug Therapy 31Surgical Procedures, Operative 31Biopsy 30Data Collection 25Magnetic Resonance Spectroscopy 25Nivolumab 21Watchful Waiting 20Immune Checkpoint Inhibitors 19Magnetic Resonance Imaging 17Standard of Care 17Therapeutics 17Immunotherapy 16palbociclib 14trastuzumab deruxtecan 14Liquid Biopsy 13Restraint, Physical 13Tomography, X-Ray Computed 13Hematologic Tests 12Radiosurgery 12Focus Groups 11Genetic Testing 11darolutamide 11enzalutamide 11pembrolizumab 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Observational × Dipeptidyl-Peptidase IV Inhibitors × 1 year × Clear all
NCT07332156 2026-01-14

Lung Cancer Risk in Type 2 Diabetes With COPD: SGLT2 Inhibitors vs. Sulfonylureas

Samsung Medical Center

Completed
21,692 enrolled
Thoracic

Diabetes Mellitus, Type 2, Disease, Lung Neoplasms, Pulmonary Disease, Chronic Obstructive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡